| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
99,290,000 |
| Market
Cap: |
1.36(B) |
| Last
Volume: |
235,243 |
Avg
Vol: |
234,590 |
| 52
Week Range: |
$8.89 - $18.8 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 10.3 |
| Insider 6 Months : 12 |
| Insider 3/6 Months : 22.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Alphatec Holdings is a holding company. Through its wholly owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., Co. is a medical technology company focused on the design, development, and improvement of technology for surgical treatment of spinal disorders. Co.'s principal procedural offerings include a variety of Approach Technologies designed to achieve clinical success in conditions from degenerative disc disease to complicated deformity and trauma. Co.'s Approach Technologies comprise intraoperative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
35,000 |
65,000 |
76,350 |
289,829 |
| Total Buy Value |
$459,550 |
$774,550 |
$948,532 |
$2,503,132 |
| Total People Bought |
2 |
3 |
4 |
7 |
| Total Buy Transactions |
2 |
3 |
9 |
23 |
| Total Shares Sold |
395,189 |
500,575 |
3,187,242 |
4,929,985 |
| Total Sell Value |
$5,642,510 |
$7,372,410 |
$47,173,314 |
$1,028,865,792 |
| Total People Sold |
5 |
5 |
10 |
11 |
| Total Sell Transactions |
12 |
17 |
34 |
78 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hunsaker Craig E |
EVP, People/Culture & GC |
• – – |
2022-04-28 |
4 |
D |
$11.54 |
$317,212 |
D/D |
(27,488) |
1,460,500 |
|
- |
|
| Tullis James L L |
Director |
– • – |
2022-04-07 |
4 |
S |
$12.99 |
$879,293 |
I/I |
(67,690) |
997,606 |
|
30% |
|
| Tullis James L L |
Director |
– • – |
2022-04-07 |
4 |
OE |
$3.50 |
$879,305 |
I/I |
251,230 |
1,036,815 |
|
- |
|
| Tullis James L L |
Director |
– • – |
2022-04-07 |
4 |
S |
$12.99 |
$21,174 |
D/D |
(1,630) |
161,512 |
|
30% |
|
| Tullis James L L |
Director |
– • – |
2022-04-07 |
4 |
OE |
$3.50 |
$21,182 |
D/D |
6,052 |
163,142 |
|
- |
|
| Howell Kelli Mari |
EVP, Clinical Strategies |
• – – |
2022-03-18 |
4 |
D |
$10.94 |
$32,164 |
D/D |
(2,940) |
544,114 |
|
- |
|
| Koning John Todd |
Chief Financial Officer |
• – – |
2022-03-18 |
4 |
D |
$10.94 |
$115,767 |
D/D |
(10,582) |
296,261 |
|
- |
|
| Hunsaker Craig E |
EVP, People/Culture & GC |
• – – |
2022-03-18 |
4 |
D |
$10.94 |
$729,173 |
D/D |
(66,652) |
1,487,988 |
|
- |
|
| Snider Brian |
EVP, Marketing |
• – – |
2022-03-18 |
4 |
D |
$10.94 |
$57,894 |
D/D |
(5,292) |
663,898 |
|
- |
|
| Sponsel David |
EVP, Sales |
• – – |
2022-03-18 |
4 |
D |
$10.94 |
$115,767 |
D/D |
(10,582) |
646,568 |
|
- |
|
| Pritzker Jennifer N. |
10% Owner |
– – • |
2022-03-11 |
4 |
B |
$10.64 |
$11,704 |
I/I |
1,100 |
3,731 |
1.5 |
-30% |
|
| Pritzker Jennifer N. |
10% Owner |
– – • |
2022-03-08 |
4 |
B |
$11.45 |
$22,910 |
I/I |
2,000 |
4,000 |
1.5 |
-41% |
|
| Pritzker Jennifer N. |
10% Owner |
– – • |
2022-03-08 |
4 |
B |
$11.39 |
$22,840 |
D/D |
2,000 |
42,200 |
2.37 |
-41% |
|
| Lish Scott |
SVP, DEVELOPMENT |
• – – |
2022-03-01 |
4 |
AS |
$10.94 |
$55,794 |
D/D |
(5,100) |
323,342 |
|
-38% |
|
| Lish Scott |
SVP, Development |
• – – |
2022-02-25 |
4 |
AS |
$10.26 |
$82,080 |
D/D |
(8,000) |
328,442 |
|
-35% |
|
| Koning John Todd |
Chief Financial Officer |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
110,161 |
306,843 |
|
- |
|
| Hunsaker Craig E |
EVP, People/Culture & GC |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
497,531 |
1,554,640 |
|
- |
|
| Lish Scott |
SVP, Development |
• – – |
2022-02-24 |
4 |
AS |
$9.44 |
$118,000 |
D/D |
(12,500) |
336,442 |
|
-34% |
|
| Lish Scott |
SVP, Development |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
88,592 |
348,942 |
|
- |
|
| Snider Brian |
EVP, Strat. Mktg. & Prod. Dev. |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
55,655 |
669,190 |
|
- |
|
| Sponsel David |
EVP, Sales |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
115,385 |
657,150 |
|
- |
|
| Howell Kelli Mari |
EVP, Clinical Strategies |
• – – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
55,655 |
547,054 |
|
- |
|
| Miles Patrick |
CEO |
• • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,085,874 |
6,112,268 |
|
- |
|
| Lish Scott |
SVP, Development |
• – – |
2022-02-22 |
4 |
AS |
$9.66 |
$45,982 |
D/D |
(4,760) |
260,350 |
|
-30% |
|
| Koning John Todd |
Chief Financial Officer |
• – – |
2021-12-16 |
4 |
B |
$11.17 |
$55,850 |
D/D |
5,000 |
196,682 |
2.74 |
5% |
|
528 Records found
|
|
Page 9 of 22 |
|
|
0.44 (3.33%) 
